Little is known how calibre and length of needles affect the stability of sclerosing foam.
Methods
Foams were made of 0.5%, 1%, 2% and 3% polidocanol, and 0.2%, 0.5%, 1% and 3% sodium tetradecyl sulfate (STS), which were mixed with air in the proportion of 4:1. These foams were ejected through needles with the length of: 4 mm, 6 mm and 13 mm, and diameter of: 0.26 mm, 0.3 mm and 0.4 mm.
Results
Foams made of more concentrated polidocanol were more stable. Regarding STS an opposite relationship was revealed. Foams made of polidocanol were more stable if ejected through a longer needle, while the length of needle did not significantly affect stability of STS foams. Foams ejected through 0.26 mm diameter needles were very unstable. In the case of 0.5% polidocanol, 0.3x6mm needle provided atypically stable foam.
Conclusion
In order to inject maximally stable foam, calibre and length of needle should be taken into account.
TessariLCavezziAFrulliniA.Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg2001;
27: 58–60.
2.
KendlerMWetzigTSimonJC.Foam sclerotherapy – a possible option in therapy of varicose veins. J Dtsch Dermatol Ges2007;
5: 648–654.
3.
PascarellaLBerganJJMekenasLV.Severe chronic venous insufficiency treated by foamed sclerosant. Ann Vasc Surg2006;
20: 83–91.
4.
Hamel-DesnosCAllaertFA.Liquid versus foam sclerotherapy. Phlebology2009;
24: 240–246.
5.
BaiTLiuYJiangW, et al.
A review of sclerosing foam stability in the treatment of varicose veins. Dermatol Surg2020;
46: 249–257.
6.
NastasaVSamarasKAmpatzidisC, et al.
Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm2015;
478: 588–596.
7.
RabeEBreuFXCavezziA, et al.; Guideline Group.
European guidelines for sclerotherapy in chronic venous disorders. Phlebology2014;
29: 338–354.
8.
BreuFXGuggenbichlerSWollmannJC.2nd European consensus meeting on foam sclerotherapy 2006 Tegernsee, Germany. VASA2008;
37: 3–29.
9.
SimkaM.Principles and technique of foam sclerotherapy and its specific use in the treatment of venous leg ulcers. Int J Low Extrem Wounds2011;
10: 138–145.
10.
Coleridge SmithP.Foam and liquid sclerotherapy for varicose veins. Phlebology2009;
24: 62–72.
11.
CavezziATessariL.Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology2009;
24: 247–251.
12.
GilletJLDonnetALauseckerM, et al.
Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology2010;
25: 261–266.
GuexJJ.Complications of sclerotherapy: an update. Dermatol Surg2010;
36: 1056–1063.
15.
GuexJJAllaertFAGilletJL, et al.
Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg2005;
31: 123–128.
16.
MorrisonNNeuhardtDL.Foam sclerotherapy: cardiac and cerebral monitoring.Phlebology2009;
24: 252–259.
17.
Raymond-MartimbeauP.Transient adverse effects positively associated with patent formen ovale after ultrasound-guided foam sclerotherapy. Phlebology2009;
24: 114–119.
18.
SimkaM.Neurologic adverse events after foam sclerotherapy. Phlebol Rev2008;
16: 129–133.
19.
CritelloCDFiorilloASMatulaTJ.Size of sclerosing foams prepared by ultrasound, mechanical agitation, and the handmade Tessari method for treatment of varicose veins. J Ultrasound Med2017;
36: 649–658.
20.
BrangerABEckmannDM.Theoretical and experimental intravascular gas embolism absorption dynamics. J Appl Physiol1999;
87: 1287–1295.
21.
BarakMKatzY.Microbubbles: pathophysiology and clinical implications.Chest2005;
128: 2918–2932.
22.
McAreeBIkponmwosaABrockbankK, et al.
Comparative stability of sodium tetradecyl sulphate (STD) and polidocanol foam: impact on vein damage in an in-vitro model. Eur J Vasc Endovasc Surg2012;
43: 721–725.
23.
Van DeurzenBCeulenRPTellingsSS, et al.
Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg2011;
37: 1448–1455.
24.
Hill D. Comparison of extemporary sclerosant foam stability by foam composition variables. In: Current Technologies and Techniques in Phlebology. Canadian Society of Phlebology Meeting, Vortrag Montreal, October 2004.
25.
PetersonJDGoldmanMP.An investigation into the influence of various gases and concentrations of sclerosants on foam stability. Dermatol Surg2011;
37: 12–17.
26.
FrulliniAFeliceFBurchielliS, et al.
High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebology2011;
26: 203–208.
